Related Experiment Video

Updated: Sep 23, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives

Paola Fuso1, Margherita Muratore1, Tatiana D'Angelo2

  • 1Department of Woman and Child Health and Public Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.

Cancers
|May 14, 2022
PubMed

Insights

Targeting the phosphatidylinositol 3-kinase (PI3K) pathway offers a promising strategy for advanced breast cancer treatment. This review explores PI3K inhibitors and future directions for metastatic breast cancer subtypes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Breast cancer remains a leading cause of female mortality, with advanced stages often incurable.
  • Existing treatments for metastatic breast cancer have limitations, necessitating novel therapeutic strategies.
  • The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB/AKT)/mammalian target of rapamycin (mTOR) pathway is crucial in breast cancer progression.

Purpose of the Study:

  • To review the rationale for targeting the PI3K pathway in breast cancer.
  • To discuss the development and clinical application of PI3K inhibitors.
  • To explore future treatment directions for various metastatic breast cancer subtypes.

Main Methods:

  • Literature review of preclinical and clinical studies on PI3K pathway targeting in breast cancer.
  • Analysis of current PI3K inhibitor development and their efficacy in metastatic settings.
  • Synthesis of data regarding the PI3K/AKT/mTOR pathway's role in breast cancer pathogenesis.

Main Results:

  • The PI3K/AKT/mTOR pathway is a significant therapeutic target due to its role in cell proliferation, survival, and motility.
  • Development of PI3K inhibitors shows potential, but challenges remain in optimizing their use.
  • Subtype-specific targeting of the PI3K pathway may improve outcomes in metastatic breast cancer.

Conclusions:

  • Targeting the PI3K pathway is a rational approach for improving outcomes in metastatic breast cancer.
  • Further research into PI3K inhibitors and combination therapies is warranted.
  • Personalized treatment strategies focusing on the PI3K/AKT/mTOR axis are crucial for different breast cancer subtypes.
Keywords:
PI3K inhibitorsbiomarkersclinical trialliquid biopsynext-generation sequencingprecision medicinereal-time PCRsubtype breast cancertarget therapy

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

566

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K